Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Biodistribution and dosimetry results form a phase III prospectively randomized controlled trial of zevalin radioimmunotherapy for low grade, follicular, or transformed B-cell non-Hodgkin's lymphoma

Biodistribution and dosimetry results form a phase III prospectively randomized controlled trial of zevalin radioimmunotherapy for low grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Critical Reviews in Oncology Hematology. 2001; 39:181-194..


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.